PMID- 20838415
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20220408
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Print)
IS  - 1759-4774 (Linking)
VI  - 7
IP  - 11
DP  - 2010 Nov
TI  - Delivering nanomedicine to solid tumors.
PG  - 653-64
LID - 10.1038/nrclinonc.2010.139 [doi]
AB  - Recent advances in nanotechnology have offered new hope for cancer detection, 
      prevention, and treatment. While the enhanced permeability and retention effect 
      has served as a key rationale for using nanoparticles to treat solid tumors, it 
      does not enable uniform delivery of these particles to all regions of tumors in 
      sufficient quantities. This heterogeneous distribution of therapeutics is a 
      result of physiological barriers presented by the abnormal tumor vasculature and 
      interstitial matrix. These barriers are likely to be responsible for the modest 
      survival benefit offered by many FDA-approved nanotherapeutics and must be 
      overcome for the promise of nanomedicine in patients to be realized. Here, we 
      review these barriers to the delivery of cancer therapeutics and summarize 
      strategies that have been developed to overcome these barriers. Finally, we 
      discuss design considerations for optimizing the delivery of nanoparticles to 
      tumors.
FAU - Jain, Rakesh K
AU  - Jain RK
AD  - Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts 
      General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 
      02114, USA. jain@steele.mgh.harvard.edu
FAU - Stylianopoulos, Triantafyllos
AU  - Stylianopoulos T
LA  - eng
GR  - T32 CA073479/CA/NCI NIH HHS/United States
GR  - R01 CA126642/CA/NCI NIH HHS/United States
GR  - R01 CA085140/CA/NCI NIH HHS/United States
GR  - R01-CA115767/CA/NCI NIH HHS/United States
GR  - P01-CA80124/CA/NCI NIH HHS/United States
GR  - R01-CA85140/CA/NCI NIH HHS/United States
GR  - R01 CA115767/CA/NCI NIH HHS/United States
GR  - P01 CA080124/CA/NCI NIH HHS/United States
GR  - R01-CA126642/CA/NCI NIH HHS/United States
GR  - R24 CA085140/CA/NCI NIH HHS/United States
GR  - T32-CA73479/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20100914
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
RN  - 0 (Ligands)
SB  - IM
MH  - Biological Transport
MH  - Drug Delivery Systems
MH  - Humans
MH  - Ligands
MH  - Lymphatic System
MH  - Nanoparticles/*therapeutic use
MH  - Neoplasms/blood supply/*drug therapy/pathology
PMC - PMC3065247
MID - NIHMS268150
EDAT- 2010/09/15 06:00
MHDA- 2011/06/03 06:00
PMCR- 2011/11/01
CRDT- 2010/09/15 06:00
PHST- 2010/09/15 06:00 [entrez]
PHST- 2010/09/15 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - nrclinonc.2010.139 [pii]
AID - 10.1038/nrclinonc.2010.139 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2010 Nov;7(11):653-64. doi: 10.1038/nrclinonc.2010.139. Epub 
      2010 Sep 14.